Literature DB >> 31073352

Interaction between warfarin and astaxanthin: A case report.

Naiyana Santiyanon1, Suwimon Yeephu1.   

Abstract

This report explains the potential interaction between warfarin and astaxanthin in a 69-year-old Thai woman with history of ischemic stroke. Before taking astaxanthin, the patient used constant doses of warfarin, atenolol, digoxin, aspirin, omeprazole, and simvastatin concomitantly for 17 days without any signs and symptoms of adverse events. One day after astaxanthin was supplemented to her treatment regimen, ecchymosis was found on the right side of her groin and thigh. On the next day, area of ecchymosis was larger. International normalized ratio (INR) values increased from 1.4 to 10.38. Warfarin and astaxanthin were withheld and vitamin K was given. Two days later, INR reduced to 1.43 and symptoms of ecchymosis were better. Causality assessment of adverse drug reaction indicated a probable relationship between bleeding symptoms and astaxanthin supplementation. Counseling the patients and caregivers as well as monitoring for potential interactions with dietary supplements should be considered as an active process in order to prevent negative outcomes to patients undergoing warfarin therapy. <Learning objective: Astaxanthin, a powerful antioxidant, has been claimed to have benefits on the cardiovascular system. The populations with high risk of atherosclerotic diseases, including patients treated with warfarin may take astaxanthin for improving their disease and overall health status. Interestingly, warfarin displays clinically significant interactions with various dietary supplements and may have potential to develop unwanted anticoagulation effects when used concomitantly with astaxanthin.>.

Entities:  

Keywords:  Astaxanthin; Drug interaction; Warfarin

Year:  2019        PMID: 31073352      PMCID: PMC6495044          DOI: 10.1016/j.jccase.2019.01.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  8 in total

1.  Astaxanthin inhibits thrombosis in cerebral vessels of stroke-prone spontaneously hypertensive rats.

Authors:  Yasuto Sasaki; Nozomi Kobara; Saori Higashino; John C Giddings; Junichiro Yamamoto
Journal:  Nutr Res       Date:  2011-10       Impact factor: 3.315

Review 2.  Advances in the diagnosis of adverse drug reactions.

Authors:  C A Naranjo; N H Shear; K L Lanctôt
Journal:  J Clin Pharmacol       Date:  1992-10       Impact factor: 3.126

3.  Anticoagulatory and antiinflammatory effects of astaxanthin in diabetic rats.

Authors:  Kung-Chi Chan; Pei-Jain Pen; Mei-Chin Yin
Journal:  J Food Sci       Date:  2012-02-06       Impact factor: 3.167

Review 4.  Warfarin and its interactions with foods, herbs and other dietary supplements.

Authors:  Edith A Nutescu; Nancy L Shapiro; Sonia Ibrahim; Patricia West
Journal:  Expert Opin Drug Saf       Date:  2006-05       Impact factor: 4.250

5.  Inhibitory effects of astaxanthin, β-cryptoxanthin, canthaxanthin, lutein, and zeaxanthin on cytochrome P450 enzyme activities.

Authors:  Yu Fen Zheng; Soo Hyeon Bae; Min Jo Kwon; Jung Bae Park; Hye Duck Choi; Wan Gyoon Shin; Soo Kyung Bae
Journal:  Food Chem Toxicol       Date:  2013-05-11       Impact factor: 6.023

Review 6.  Astaxanthin: a potential therapeutic agent in cardiovascular disease.

Authors:  Robert G Fassett; Jeff S Coombes
Journal:  Mar Drugs       Date:  2011-03-21       Impact factor: 5.118

Review 7.  Astaxanthin: sources, extraction, stability, biological activities and its commercial applications--a review.

Authors:  Ranga Rao Ambati; Siew Moi Phang; Sarada Ravi; Ravishankar Gokare Aswathanarayana
Journal:  Mar Drugs       Date:  2014-01-07       Impact factor: 5.118

8.  Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats.

Authors:  Zu-Yue Deng; Wei-Guang Shan; Shen-Feng Wang; Meng-Mei Hu; Yan Chen
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.